Latest Press Releases

Maryland-based biotech company Deka Biosciences ("Deka") announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by additional investors including Leaps by Bayer, Lumira Ventures, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced that "LEQEMBI® Intravenous Infusion" (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD). The regulatory approval in Japan announced today, entitles BioArctic to a milestone of EUR 17 M.

Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510(k) clearance and the launch of our new CRYOcheck™ Factor VIII Deficient Plasma with VWF in the U.S.

Neoss Group, a leading innovator in dental implant solutions, is proud to announce the fast and easy-to-use wireless intraoral scanner, NeoScan™ 2000. This follows the success of last year's launch of the NeoScan™ 1000.

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneering pharmaceutical technology company specializing in innovative wellness products, is elated to announce the appointment of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Scientific Advisory Board (SAB). Dr. Pergolizzi, a distinguished expert in the field of pain management and critical care medicine, will be instrumental in the Company's upcoming planned FDA filing for human medications.

EQUASHIELD, a pioneer in closed system transfer devices (CSTDs) and automated pharmacy compounding solutions, is thrilled to announce its remarkable achievement of being named by the Pharmacy Purchasing & Products as the most used device in the preparation and administration of hazardous drugs for five consecutive years.

Following convincing results from a recent In-Vitro study, the Danish biotech company, Tetra Pharm Technologies, announces successful In-Vivo study results of its candidate compound, TPT0301.

Alliance for Multispecialty Research (AMR), a leading integrated research site organization, announced the appointment of Kari L. Delahunty as the Company's first Chief Operating Officer. An experienced leader, Delahunty will help support the growth and expansion of AMR's award-winning clinical research site network in new and existing markets across the U.S.

CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, announced financial results for the second quarter ended June 30, 2023, and provided a corporate update on its programs.

GSK plc (LSE/NYSE: GSK) announced that AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is now available in the US at all major retail pharmacies.